Filing Flows › Comparisons › VCEL vs ADPT
Vericel vs Adaptive Biotechnologies: VCEL and ADPT compared
Vericel is the larger company: $85.4M of revenue in its latest quarter (Q3 2026) against $83.9M for Adaptive Biotechnologies (Q3 2026). Vericel is growing faster (+26% against -11% a year earlier). Vericel is more profitable, with an operating margin of 14.3% against -0.5%.
Where the money goes: VCEL and ADPT
Vericel (VCEL) · Q3 2026
Vericel, Q3 2026: revenue $85.4M (+26% year over year), operating margin 14.3%, net earnings $14.2M, operating cash flow $17.7M. The chart follows the revenue to costs, profit and cash.
Adaptive Biotechnologies (ADPT) · Q3 2026
Adaptive Biotechnologies, Q3 2026: revenue $83.9M (-11% year over year), operating margin -0.5%, net earnings $2.8M, operating cash flow $9.6M. The chart follows the revenue to costs, profit and cash.
| Vericel (VCEL) | Adaptive Biotechnologies (ADPT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $85.4M | $83.9M |
| Revenue growth, Y/Y | +26% | -11% |
| Gross margin | 73.3% | — |
| Operating margin | 14.3% | -0.5% |
| Net earnings | $14.2M | $2.8M |
| Net margin | 16.6% | 3.3% |
| Operating cash flow | $17.7M | $9.6M |
| Free cash flow | $15.7M | $7.7M |
| Market value | $2.2B | — |
| P/E | 91.9× | — |
| Analysts’ mean target | $59.71 | — |
Questions
Which is bigger, Vericel or Adaptive Biotechnologies?
Vericel is the larger company: $85.4M of revenue in its latest quarter (Q3 2026) against $83.9M for Adaptive Biotechnologies (Q3 2026).
Is Vericel or Adaptive Biotechnologies growing faster?
Vericel is growing faster (+26% against -11% a year earlier).
Which is more profitable, Vericel or Adaptive Biotechnologies?
Vericel is more profitable, with an operating margin of 14.3% against -0.5%.
More: Vericel earnings · how Vericel makes money · Adaptive Biotechnologies earnings · how Adaptive Biotechnologies makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.